Gilder Gagnon Howe & Co. LLC decreased its stake in shares of Evolent Health, Inc (NYSE:EVH) by 71.8% during the second quarter, Holdings Channel reports. The firm owned 73,735 shares of the technology company’s stock after selling 187,831 shares during the period. Gilder Gagnon Howe & Co. LLC’s holdings in Evolent Health were worth $1,869,000 as of its most recent filing with the SEC.
Several other institutional investors have also added to or reduced their stakes in the stock. Swiss National Bank boosted its position in shares of Evolent Health by 51.7% in the first quarter. Swiss National Bank now owns 61,000 shares of the technology company’s stock valued at $1,360,000 after buying an additional 20,800 shares during the period. Fox Run Management L.L.C. purchased a new position in shares of Evolent Health during the second quarter valued at about $363,000. US Bancorp DE boosted its position in shares of Evolent Health by 0.3% in the first quarter. US Bancorp DE now owns 5,654 shares of the technology company’s stock valued at $126,000 after buying an additional 19 shares during the period. PEAK6 Investments L.P. purchased a new position in shares of Evolent Health during the first quarter valued at about $342,000. Finally, AQR Capital Management LLC boosted its position in shares of Evolent Health by 134.7% in the fourth quarter. AQR Capital Management LLC now owns 25,657 shares of the technology company’s stock valued at $380,000 after buying an additional 14,723 shares during the period. Institutional investors own 73.16% of the company’s stock.
Shares of Evolent Health, Inc (NYSE:EVH) opened at 18.15 on Thursday. The firm’s market capitalization is $1.05 billion. Evolent Health, Inc has a 12 month low of $14.50 and a 12 month high of $27.50. The firm has a 50-day moving average price of $25.20 and a 200 day moving average price of $22.71.
Evolent Health (NYSE:EVH) last announced its quarterly earnings results on Monday, August 7th. The technology company reported ($0.13) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.13). The business had revenue of $107.30 million for the quarter, compared to analyst estimates of $104.45 million. Evolent Health had a negative return on equity of 6.44% and a negative net margin of 17.57%. Evolent Health’s quarterly revenue was up 89.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.20) EPS. On average, analysts anticipate that Evolent Health, Inc will post ($0.42) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This story was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/2797419/evolent-health-inc-evh-shares-sold-by-gilder-gagnon-howe-co-llc.html.
EVH has been the topic of several research analyst reports. Zacks Investment Research cut Evolent Health from a “buy” rating to a “hold” rating in a research note on Thursday, May 4th. Jefferies Group LLC restated a “buy” rating and set a $28.00 price objective on shares of Evolent Health in a research note on Thursday, April 13th. Cowen and Company restated an “outperform” rating and set a $35.00 price objective on shares of Evolent Health in a research note on Wednesday, June 28th. BidaskClub cut Evolent Health from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Finally, ValuEngine cut Evolent Health from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $29.90.
In related news, Director Cheryl Scott sold 5,477 shares of the business’s stock in a transaction on Friday, May 19th. The stock was sold at an average price of $23.51, for a total value of $128,764.27. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Frank J. Williams sold 16,300 shares of the business’s stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $23.73, for a total value of $386,799.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,153,967 shares of company stock worth $253,648,377. 8.79% of the stock is owned by insiders.
About Evolent Health
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
Want to see what other hedge funds are holding EVH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evolent Health, Inc (NYSE:EVH).
Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.